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The incidence of central nervous system diseases is increasing 
due to elongation of lifetime of humans. It is related with injuries, 
neurodegenerative diseases, intoxication, as well as natural processes 
associated with ageing. 
As a result, medicinal chemistry, which has emerged from organic 
chemistry, has undergone multiple trends and – depending on the 
indications – with various results. Many diseases have been eradicated, 
resulting in better quality of life and its elongation (e.g. analgesic, 
nontropic drugs). Other indications have arose and became unmet 
medical needs (e.g. neuropathic pain). Moreover, there are diseases 
which were poorly addressed fifty years ago and are still today (e.g. 
epilepsy, major depressive disorder). 
Molecular modeling has aided discovery of some new drugs, 
due to belief that only specific ligands towards subtypes of receptors 
may be safe enough. This process resulted in creation of compound 
libraries and development of big pharma programs related with search 
for a specific drug towards single conditions. However, this strategy 
is limited to indications where the target is well known and influence 
on the target is sufficient to treat the symptom. In the cases where the 
pathomechanism of the disease is not well known – in vivo models are 
used for activity screening of compounds. If a specific drug active in a 
single mechanism of action is not effective enough, polytherapy is used, 
questioning sometimes the rationale for specific target development.
Due to the above fact, the expression “dirty pharmacophore” which 
meant a drug binding to many receptors, has been more and more often 
replaced by “rich pharmacophore”. However, the new challenge is to 
obtain the desired cocktail of bound receptors, and the expected in vivo 
outcome, bearing in mind the complexity of ADME-Tox processes.
Another approach contrary to molecular modeling is synthesis of 
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analogs of used drugs, or synthesis of new compounds which possess 
structural elements observed in biologically active compounds. In such 
strategy, a typical expression is “drug-like look” of the structure, using 
intuitively the Lipinski rule of five, taking into account parameters 
such as lipophilicity, pKa, as well as potential metabolism based on the 
knowledge of toxicity of old drugs or natural compounds.
New receptors described by biologists have been another starting 
point for new active compound design. This in turn implies doubt 
related with pharmacological activity, safety, long-term toxicity, 
addiction, as well as influence on progress of the disease. Finally, it must 
be taken into account that proof of hypothesis related with such ligand 
activity is visible in humans, over ten years of research performed on 
thousands of animals.
The final aspect to be mentioned is quantities of compounds 
needed for screening which influence the methods used for their 
synthesis. The more the target is defined, the more molecular modeling 
approach is used, and the quantities are relatively small (about 15 
mg) leaving possibility for a complicated structure. In case of in vivo 
screening, usually quantities of about 500 mg may be needed – which 
leaves possibility only for relatively simple structures and effective 
methods of synthesis with yield above 50%. As a consequence, the term 
“click chemistry” has arisen as a necessary limitation of the cost of 
research and medicines themselves. New peptide drugs have answered 
many diseases, but the cost and complexity, as well as immunological 
response to them limit their use to the most justified cases. On the other 
hand, peptides found their use in cosmetics chemistry, where they are 
used topically.
As a summary, it seems that medicinal chemistry will constantly 
develop in terms of therapeutic areas, chemical structures, and methods 
of synthesis.
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